Showing results (121-130 of 146) with videos related to
Sort By:
Pageof 15
Journal for Immunotherapy of Cancer|February 23, 2022
Toripalimab plus axitinib in patients with metastatic mucosal melanoma: 3-year survival update and biomarker analysisSiming Li, Xiaowen Wu, Xieqiao Yan, et al.Journal for Immunotherapy of Cancer|February 6, 2025
Oncolytic virus OH2 extends survival in patients with PD-1 pretreated melanoma: phase Ia/Ib trial results and biomarker insightsXuan Wang, Hui Tian, Zhihong Chi, et al.Frontiers in Oncology|June 7, 2021
Risk Models for Advanced Melanoma Patients Under Anti-PD-1 Monotherapy-<i>Ad hoc</i> Analyses of Pooled Data From Two Clinical TrialsXue Bai, Jie Dai, Caili Li, et al.Frontiers in Oncology|September 10, 2021
Overall Survival of Patients With Unresectable or Metastatic BRAF V600-Mutant Acral/Cutaneous Melanoma Administered Dabrafenib Plus Trametinib: Long-Term Follow-Up of a Multicenter, Single-Arm Phase IIa TrialLili Mao, Ya Ding, Xue Bai, et al.Signal Transduction and Targeted Therapy|November 21, 2024
Neoadjuvant oncolytic virus orienx010 and toripalimab in resectable acral melanoma: a phase Ib trialJiayong Liu, Xuan Wang, Zhongwu Li, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 24, 2017
Frequent Genetic Aberrations in the CDK4 Pathway in Acral Melanoma Indicate the Potential for CDK4/6 Inhibitors in Targeted TherapyYan Kong, Xinan Sheng, Xiaowen Wu, et al.Journal of Extracellular Vesicles|March 26, 2025
Dynamic Change of PD-L2 on Circulating Plasma Extracellular Vesicles as a Predictor of Treatment Response in Melanoma Patients Receiving Anti-PD-1 TherapyLinzi Sun, Xiaoting Wei, Qian Zhao, et al.European Journal of Cancer (Oxford, England : 1990)|March 26, 2021
Palbociclib in advanced acral melanoma with genetic aberrations in the cyclin-dependent kinase 4 pathwayLili Mao, Jie Dai, Yabin Cao, et al.Frontiers in Oncology|July 18, 2022
Proliferation Marker Ki67 as a Stratification Index of Adjuvant Chemotherapy for Resectable Mucosal MelanomaLirui Tang, Xiaoting Wei, Caili Li, et al.Theranostics|March 15, 2019
MicroRNA-23a-3p Inhibits Mucosal Melanoma Growth and Progression through Targeting Adenylate Cyclase 1 and Attenuating cAMP and MAPK PathwaysMeng Ma, Jie Dai, Huan Tang, et al.Pageof 15